Editas Medicine, Inc.
EDIT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 110.8% | -23.2% | -84.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -291.6% | -1,380.1% | -1,544.8% | -107.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -333% | -1,487.8% | -1,633.5% | -148.3% |
| EPS Diluted | -0.28 | -0.63 | -0.92 | -0.55 |
| % Growth | 55.6% | 31.5% | -67.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |